Table 2: Treatment Outcomes in the Intention-to-Treat Population.

Outcome All, n = 50 SOF/LDV, n = 31 SOF/VEL, n = 7 EBR/GZR, n = 8 OBV/PTV/r + DSV +/- RBV, n = 4
SVR12 42 (84) 26 (84) 6 (86) 6 (75) 4 (100)
SVR12 according to GT
GT1 36/43 (84) 25/30 (83) 1/1 (100) 6/8 (75) 4/4 (100)
GT1a 26/30 (87) 17/21 (81) - 7/7 (100) 2/2 (100)
GT1b 11/13 (85) 8/9 (89) 1/1 (100) 0/1 (0) 2/2 (100)
GT2 3/3 (100) - 3/3 (100) - -
GT3 2/3 (67) - 2/3 (67) - -
GT4 1/1 (100) 1/1 (100) - - -
SVR12 according to liver fibrosis status
F0-F2 18/22 (82) 12/14 (86) 3/4 (75) 2/3 (67) 1/1 (100)
F3-F4 24/28 (86) 14/17 (82) 3/3 (100) 4/5 (80) 3/3 (100)
Virologic failure
On-treatment failure 1 (2)* 1 (3)*
Post-treatment relapse 3 (6) 2 (6) 1 (14) 0 0
Failure due to other reasons
LTFU after EOT 3 (6) 2 (6) 0 1 (13) 0
Death 2 (4)* 1 (3)* 0 1 (13) 0

DSV: Dasabuvir; EBR/GZR: Elbasvir/grazoprevir; EOT: End of treatment; F0-F2: Fibrosis stage 0 to 2; F3-F4: Fibrosis stage 3 (advanced fibrosis) to 4 (cirrhosis); GT: Genotype; OBV/PTV/r: Ombitasvir/paritaprevir/ritonavir; LTFU: Lost to follow up; RBV: Ribavirin; SOF/LDV: Sofosbuvir/ledipasvir; SOF/VEL: Sof osbuvir/velpatasvir.

*One patient is counted twice; this patient experienced on-treatment failure and died.